Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand?

xlomafota13 shared this article with you from Inoreader Sialadenitis as a complication of radioiodine therapy in patients with thyroid cancer: where do we stand? Via radioactive iodine Hormones (Athens). 2021 Jun 18. doi: 10.1007/s42000-021-00304-3. Online ahead of print. ABSTRACT PURPOSE: This study aims to elaborate on the current knowledge concerning the mechanism, frequency, clinical manifestations, diagnostic procedures, prevention, and management of radioactive iodine (RAI)-induced sialadenitis in patients receiving treatment for differentiated thyroid cancer (DTC). METHODS: A review of the literature was carried out through the " www.ncbi.nlm.nih.gov /pubmed " database focusing on the results of the past decade. RESULTS: The high concentration of RAI in the salivary glands results in high beta radiation exposure of the striated duct cells and stem cells. This exposure leads to acute and/or chronic sialadenitis with obstructive symptoms and progressive loss of salivary gland function and xerostomia, with severe impact on patients' quality of life. No standard diagnostic method has been established. As far as prevention is concerned, many approaches have been proposed, such as sialogogues, local massage, vitamin E, and amifostine administration. Although there is no unanimity as to their effectiveness, the use of sialogogues is recommended. Treatment includes conservative drug therapy and sialendoscopy when necessary. CONCLUSION: RAI-induced sialadenitis has a major impact on patients' quality of life. Due to the good prognosis of DTC, the reduction of sialadenitis and its prognosis, prevention, and treatment constitut e a priority for the overall treatment of these patients. Further studies that will establish a coherent treatment protocol for this condition are necessary. PMID:34143403 | DOI:10.1007/s42000-021-00304-3 View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.